Correct!
5. All of the above

The mainstay of NGV treatment is immunosuppression in order to induce complete remission of the disease. The options for this purpose include steroids, rituximab, cyclophosphamide, methotrexate and plasma exchange.
The combination of agents is dependent on the severity of disease. For mild disease glucocorticoids in combinations with methotrexate is considered a good starting point. Patients with moderate to severe disease should have their treatment initiated with glucocorticoids plus cyclophosphamide or rituximab.

Plasma exchange is indicated in addition to medication therapy for those patients who meet the following criteria serum creatinine > 5.7, requirement for dialysis and pulmonary hemorrhage.

References

1. Abigail RL, Marvin IS. Diffuse alveolar hemorrhage. Chest. 2010;137(5):1164-71. [CrossRef] [PubMed]
2. de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, Jayne DR, Gaskin G, Rasmussen N, Noël LH, Ferrario F, Waldherr R, Hagen EC, Bruijn JA, Bajema IM.. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol. 2006;17:2264-74. [CrossRef] [PubMed]
3. Finkielman JD, Lee AS, Hummel AM, et al. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med. 2007;120:643.e9-14. [PubMed]

Home/Pulmonary